Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study

The objective of this study was to evaluate the clinical files of patients with RRMS who started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or fingolimod (FTY)). This was a historical cohort study. We compared the effect according to the Expanded Disability Status Scale...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Preciado, Martha Rocio, Marquez-Pedroza, Jazmin, Sánchez-Rosales, Nayeli Alejandra, García-Rivera, José de Jesús, Kobayashi-Gutiérrez, Antonio, Torres-Mendoza, Blanca Miriam, Chavarría-Avila, Efraín, Montaño-Serrano, Raúl Alejandro, Cortes-Enriquez, Fernando, Mireles-Ramírez, Mario Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267823/
https://www.ncbi.nlm.nih.gov/pubmed/35806869
http://dx.doi.org/10.3390/jcm11133584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267823/
https://www.ncbi.nlm.nih.gov/pubmed/35806869
http://dx.doi.org/10.3390/jcm11133584

Ejemplares similares